Translation Initiation Factor IF-2-like: A Potential Drug Target and Biomarker

Target Name: Translation initiation factor IF-2-like, transcript variant X1

NCBI ID: G112267947

Translation initiation factor IF-2-like, transcript variant X1

Other Name(s): Translation initiation factor IF-2-like | Uncharacterized protein LOC112267947 (isoform X1) | LOC112267947 variant X1

Translation Initiation Factor IF-2-like: A Potential Drug Target and Biomarker

Translation initiation factor IF-2-like (IF2L) is a protein that plays a crucial role in the initiation of protein translation.IF2L is a member of the IF2 family, which includes several similar proteins that share a conserved catalytic core and a distinct N-terminus.IF2L is highly conserved across various species, including humans, and has been implicated in various cellular processes, including cell signaling, DNA replication, and neurodegeneration.

Recent studies have suggested that IF2L may be a drug target or a biomarker, depending on the context.IF2L has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.IF2L has also been identified as a potential therapeutic target in several drug development programs.

IF2L as a Drug Target

IF2L has been identified as a potential drug target due to its involvement in several cellular processes that are associated with disease.IF2L has been shown to be involved in cell signaling, including the regulation of cell adhesion, migration, and survival.IF2L has also been linked to the regulation of DNA replication, cell cycle progression, and cell growth.

IF2L has been shown to contribute to the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.For example,IF2L has been shown to be involved in the development and progression of breast cancer.IF2L has also been linked to the development of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

IF2L has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.IF2L has been shown to be expressed in several disease tissues, including cancer, neurodegenerative diseases, and autoimmune disorders.IF2L has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

IF2L as a Biomarker

IF2L has also been identified as a potential biomarker for several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.IF2L has been shown to be expressed in several disease tissues, including cancer, neurodegenerative diseases, and autoimmune disorders.IF2L has also been shown to play a role in the regulation of cellular processes, including cell adhesion, migration, and survival.

IF2L has been shown to contribute to the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.IF2L has also been linked to the regulation of DNA replication, cell cycle progression, and cell growth.

IF2L is a protein that has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.IF2L is highly conserved across various species and has been implicated in various cellular processes.IF2L is a potential drug target and biomarker, and further research is needed to fully understand its role in disease.

Protein Name: Translation Initiation Factor IF-2-like, Transcript Variant X1

The "Translation initiation factor IF-2-like, transcript variant X1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about Translation initiation factor IF-2-like, transcript variant X1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets